These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10147234)

  • 1. Costs of epoetin in patients with AIDS.
    Henry DH
    Pharmacoeconomics; 1994 May; 5(5):446-7. PubMed ID: 10147234
    [No Abstract]   [Full Text] [Related]  

  • 2. A cost-effectiveness analysis of epoetin usage for patients with AIDS.
    Cantor SB; Carson RW; Spann SJ
    Pharmacoeconomics; 1993 Mar; 3(3):244-9. PubMed ID: 10146947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epoetin alpha approved for anemic AIDS patients.
    J Am Osteopath Assoc; 1991 Jun; 91(6):538. PubMed ID: 1874651
    [No Abstract]   [Full Text] [Related]  

  • 4. Comments on Clinical and economic comparison of epoetin alfa and darbepoetin alfa.
    Vanscoy GJ
    Curr Med Res Opin; 2004 Sep; 20(9):1459-60; author reply 1462-3. PubMed ID: 15383195
    [No Abstract]   [Full Text] [Related]  

  • 5. A decision analysis comparing three dosage regimens of subcutaneous epoetin in continuous ambulatory peritoneal dialysis.
    Piccoli A; Puggia RM; Fusaro M; Favaro E; Pillon L
    Pharmacoeconomics; 1995 May; 7(5):444-56. PubMed ID: 10155331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.
    Martin SC; Gagnon DD; Zhang L; Bokemeyer C; Van Marwijk Kooy M; van Hout B
    Pharmacoeconomics; 2003; 21(16):1153-69. PubMed ID: 14594437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comments on Clinical and economic comparison of epoetin alfa and darbepoetin alfa.
    Sullivan SD
    Curr Med Res Opin; 2004 Sep; 20(9):1461; author reply 1462-3. PubMed ID: 15487107
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA approves treatment IND protocol for use of erythropoietin product in AIDS.
    Clin Pharm; 1989 Sep; 8(9):607. PubMed ID: 2791478
    [No Abstract]   [Full Text] [Related]  

  • 9. Low-dosage epoetin in maintenance haemodialysis: costs and quality-of-life improvement.
    Harris DC
    Pharmacoeconomics; 1994 Jan; 5(1):18-28. PubMed ID: 10146863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic analysis of epoetin alfa in critically ill trauma patients.
    Chui BK; Pannu N; Hazel M; Dong J; Tonelli M; Klarenbach SW
    J Trauma Acute Care Surg; 2012 Jul; 73(1):195-201. PubMed ID: 22710785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group.
    Maier RF; Obladen M; Scigalla P; Linderkamp O; Duc G; Hieronimi G; Halliday HL; Versmold HT; Moriette G; Jorch G
    N Engl J Med; 1994 Apr; 330(17):1173-8. PubMed ID: 8139627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia.
    Cremieux PY; Finkelstein SN; Berndt ER; Crawford J; Slavin MB
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):459-72. PubMed ID: 10662393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical utility of epoetin in cancer patients: a matter of perspective.
    Barosi G; Marchetti M
    Haematologica; 2000 May; 85(5):449-50. PubMed ID: 10800156
    [No Abstract]   [Full Text] [Related]  

  • 14. Darbepoetin alpha is highly cost-effective compared with epoetin alpha in the treatment of renal anemia: a brief report from a hemodialysis clinic in Japan.
    Nakagawa T
    Ther Apher Dial; 2008 Dec; 12(6):531-2. PubMed ID: 19140854
    [No Abstract]   [Full Text] [Related]  

  • 15. A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries.
    Leese B; Hutton J; Maynard A
    Pharmacoeconomics; 1992 May; 1(5):346-56. PubMed ID: 10146999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin therapy for premature infants: cost without benefit?
    Zipursky A
    Pediatr Res; 2000 Aug; 48(2):136. PubMed ID: 10926284
    [No Abstract]   [Full Text] [Related]  

  • 17. Recombinant erythropoietin for zidovudine-induced anemia in AIDS.
    Kuehl AK; Noormohamed SE
    Ann Pharmacother; 1995; 29(7-8):778-9. PubMed ID: 8520096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Song X; Long SR; Marder WD; Sullivan SD; Kallich J
    Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic evaluation of an evidence-based institutional epoetin-utilization management program.
    Buckley MS; Kane-Gill SL; Patel SA
    Clin Ther; 2013 Mar; 35(3):294-302. PubMed ID: 23465799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.
    Whittington R; Barradell LB; Benfield P
    Pharmacoeconomics; 1993 Jan; 3(1):45-82. PubMed ID: 10146987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.